These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22784008)

  • 1. Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
    Díaz JL; Cuberes R; Berrocal J; Contijoch M; Christmann U; Fernández A; Port A; Holenz J; Buschmann H; Laggner C; Serafini MT; Burgueño J; Zamanillo D; Merlos M; Vela JM; Almansa C
    J Med Chem; 2012 Oct; 55(19):8211-24. PubMed ID: 22784008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of novel sigma-1 receptor antagonists based on pyrimidine scaffold as agents for treating neuropathic pain.
    Lan Y; Chen Y; Cao X; Zhang J; Wang J; Xu X; Qiu Y; Zhang T; Liu X; Liu BF; Zhang G
    J Med Chem; 2014 Dec; 57(24):10404-23. PubMed ID: 25420090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of two pharmacophoric systems: synthesis and pharmacological evaluation of spirocyclic pyranopyrazoles with high σ₁ receptor affinity.
    Schläger T; Schepmann D; Lehmkuhl K; Holenz J; Vela JM; Buschmann H; Wünsch B
    J Med Chem; 2011 Oct; 54(19):6704-13. PubMed ID: 21859078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization.
    Romero L; Zamanillo D; Nadal X; Sánchez-Arroyos R; Rivera-Arconada I; Dordal A; Montero A; Muro A; Bura A; Segalés C; Laloya M; Hernández E; Portillo-Salido E; Escriche M; Codony X; Encina G; Burgueño J; Merlos M; Baeyens JM; Giraldo J; López-García JA; Maldonado R; Plata-Salamán CR; Vela JM
    Br J Pharmacol; 2012 Aug; 166(8):2289-306. PubMed ID: 22404321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationship study of a new series of selective σ(1) receptor ligands for the treatment of pain: 4-aminotriazoles.
    Díaz JL; Christmann U; Fernández A; Torrens A; Port A; Pascual R; Álvarez I; Burgueño J; Monroy X; Montero A; Balada A; Vela JM; Almansa C
    J Med Chem; 2015 Mar; 58(5):2441-51. PubMed ID: 25658964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of sigma-1 receptors in paclitaxel-induced neuropathic pain in mice.
    Nieto FR; Cendán CM; Sánchez-Fernández C; Cobos EJ; Entrena JM; Tejada MA; Zamanillo D; Vela JM; Baeyens JM
    J Pain; 2012 Nov; 13(11):1107-21. PubMed ID: 23063344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Operant self-administration of a sigma ligand improves nociceptive and emotional manifestations of neuropathic pain.
    Bura AS; Guegan T; Zamanillo D; Vela JM; Maldonado R
    Eur J Pain; 2013 Jul; 17(6):832-43. PubMed ID: 23172791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of a novel sigma-1 receptor antagonist based on 3,4-dihydro-2(1H)-quinolinone scaffold as a potential analgesic.
    Lan Y; Chen Y; Xu X; Qiu Y; Liu S; Liu X; Liu BF; Zhang G
    Eur J Med Chem; 2014 May; 79():216-30. PubMed ID: 24735647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the molecular interactions of the potent analgesic S1RA with the σ1 receptor.
    Laurini E; Da Col V; Wünsch B; Pricl S
    Bioorg Med Chem Lett; 2013 May; 23(10):2868-71. PubMed ID: 23582276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists.
    Tabrizi MA; Baraldi PG; Preti D; Romagnoli R; Saponaro G; Baraldi S; Moorman AR; Zaid AN; Varani K; Borea PA
    Bioorg Med Chem; 2008 Mar; 16(5):2419-30. PubMed ID: 18077171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel 1,3-dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as potent and selective A₂B adenosine receptor antagonists.
    Baraldi PG; Baraldi S; Saponaro G; Preti D; Romagnoli R; Piccagli L; Cavalli A; Recanatini M; Moorman AR; Zaid AN; Varani K; Borea PA; Tabrizi MA
    J Med Chem; 2012 Jan; 55(2):797-811. PubMed ID: 22148859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of antiparasitic activities of new 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine derivatives.
    Kuettel S; Zambon A; Kaiser M; Brun R; Scapozza L; Perozzo R
    J Med Chem; 2007 Nov; 50(23):5833-9. PubMed ID: 17949068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and pharmacological evaluation of a potent and selective σ1 receptor antagonist with high antiallodynic activity.
    Utech T; Köhler J; Buschmann H; Holenz J; Vela JM; Wünsch B
    Arch Pharm (Weinheim); 2011 Jul; 344(7):415-21. PubMed ID: 21598296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of sigma 1 receptors alleviates sensory signs of diabetic neuropathy in rats.
    Paniagua N; Girón R; Goicoechea C; López-Miranda V; Vela JM; Merlos M; Martín Fontelles MI
    Eur J Pain; 2017 Jan; 21(1):61-72. PubMed ID: 27341510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The σ(1) receptor antagonist S1RA is a promising candidate for the treatment of neurogenic pain.
    Wünsch B
    J Med Chem; 2012 Oct; 55(19):8209-10. PubMed ID: 22951043
    [No Abstract]   [Full Text] [Related]  

  • 17. Discovery and structure-activity relationship of 3-methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide (APD791): a highly selective 5-hydroxytryptamine2A receptor inverse agonist for the treatment of arterial thrombosis.
    Xiong Y; Teegarden BR; Choi JS; Strah-Pleynet S; Decaire M; Jayakumar H; Dosa PI; Casper MD; Pham L; Feichtinger K; Ullman B; Adams J; Yuskin D; Frazer J; Morgan M; Sadeque A; Chen W; Webb RR; Connolly DT; Semple G; Al-Shamma H
    J Med Chem; 2010 Jun; 53(11):4412-21. PubMed ID: 20455563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology.
    Adams JW; Ramirez J; Shi Y; Thomsen W; Frazer J; Morgan M; Edwards JE; Chen W; Teegarden BR; Xiong Y; Al-Shamma H; Behan DP; Connolly DT
    J Pharmacol Exp Ther; 2009 Oct; 331(1):96-103. PubMed ID: 19628629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-(tetralin-1-yl)- and 4-(naphthalen-1-yl)alkyl derivatives of 1-cyclohexylpiperazine as sigma receptor ligands with agonist sigma2 activity.
    Berardi F; Ferorelli S; Abate C; Colabufo NA; Contino M; Perrone R; Tortorella V
    J Med Chem; 2004 Apr; 47(9):2308-17. PubMed ID: 15084129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of N-(3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-1H-indole-carboxamides as cholecystokinin antagonists.
    Lattmann E; Singh H; Boonprakob Y; Lattmann P; Sattayasai J
    J Pharm Pharmacol; 2006 Mar; 58(3):393-401. PubMed ID: 16536908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.